2018年:業績(論文)

原著

  1. Araki M, Yang Y, Imai M, Mizukami Y, Kihara Y, Sunami Y, Masubuchi N, Edahiro Y, Hironaka Y, Osaga S, Ohsaka A, Komatsu N. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation. Leukemia. 2018. [Epub ahead of print]
  2. Watanabe N, Kitahara H, Iwao N, Ohta Y, Koike M, Komatsu N. Retroperitoneal relapse in an older patient with multiple myeloma during pomalidomide and dexamethasone treatment. Geriatr Gerontol Int. 2018;18(6):977-9.
  3. Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, Takaku T, Iriyama N, Sato E, Fujita H, Hatta Y, Komatsu N, Asou N, Kizaki M, Kawaguchi T. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol. 2018;35(3):38.
  4. Takei H, Edahiro Y, Mano S, Masubuchi N, Mizukami Y, Imai M, Morishita S, Misawa K, Ochiai T, Tsuneda S, Endo H, Nakamura S, Eto K, Ohsaka A, Araki M, Komatsu N. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations. Br J Haematol. 2018;181(6):791-802.
  5. Takaku T, Iriyama N, Mitsumori T, Sato E, Gotoh A, Kirito K, Noguchi M, Koike M, Sakamoto J, Oba K, Komatsu N. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group. Oncology. 2018;94(2):85-91.
  6. Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score. Leuk Lymphoma. 2018;59(5):1105-12.
  7. Oritani K, Ohishi K, Okamoto S, Kirito K, Komatsu N, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Okada H, Amagasaki T, Wakase S, Shimozuma K, Akashi K. Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis. Curr Med Res Opin. 2018;34(3):531-7.
  8. Ochiai T, Yasuda H, Araki M, Misawa K, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort. Eur J Haematol. 2018;100(6):544-9.
  9. Nitta H, Gotoh A, Tanaka M, Sekiguchi Y, Ota Y, Noguchi M, Komatsu N. Pleural effusion at diagnosis predicts extremely poor outcomes in patients with diffuse large B-cell lymphoma harbouring MYC rearrangement. Br J Haematol. 2018. [Epub ahead of print]
  10. Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto KJ, Fujita H, Fujioka I, Kimura Y, Aisa Y, Iwanaga E, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Med Oncol. 2018;35(7):99.
  11. Nakamura A, Misawa S, Chonan M, Kawakami T, Horii T, Komatsu N, Ohsaka A. Efficacy of PCR-based open reading frame typing assay for outbreak investigation of metallo-beta-lactamase-producing Pseudomonas aeruginosa in hematology unit. J Infect Chemother. 2018. [Epub ahead of print]
  12. Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol. 2018;107(6):673-80.
  13. Kirito K, Okamoto S, Ohishi K, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Oritani K, Akashi K, Okada H, Amagasaki T, Suzuki K, Yonezu T, Komatsu N. Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. Int J Hematol. 2018;107(1):92-7.
  14. Inokuchi K, Nakayama K, Tauchi T, Takaku T, Yokose N, Yamaguchi H, Kumagai T, Komatsu N, Ohyashiki K. Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations. Leuk Res. 2018;65:74-9.
  15. Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol. 2018. [Epub ahead of print]
  16. Asakura K, Azechi T, Sasano H, Matsui H, Hanaki H, Miyazaki M, Takata T, Sekine M, Takaku T, Ochiai T, Komatsu N, Shibayama K, Katayama Y, Yahara K. Rapid and easy detection of low-level resistance to vancomycin in methicillin-resistant Staphylococcus aureus by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. PLoS One. 2018;13(3):e0194212.
  17. Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T, Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi K, Tamura H. Clinical impact of serum soluble SLAMF7 in multiple myeloma. Oncotarget. 2018;9(78): 34784-34793.
  18. Sakamoto K, Katayama R, Asaka R, Sakata S, Baba S, Nakasone H, Koike S, Tsuyama N, Dobashi A, Sasaki M, Ichinohasama R, Takakuwa E, Yamazaki R, Takizawa J, Maeda T, Narita M, Izutsu K, Kanda Y, Ohshima K, Takeuchi K. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia. 2018 Dec;32(12):2590-2603.

英文症例報告

  1. Edahiro Y, Ando J, Suzuki T, Fukumura Y, Masuda A, Sakayori S, Takeda J, Maruyama Y, Makino S, Itakura A, Komatsu N. Multiple Placental Infarcts in a Pregnant Woman with Essential Thrombocythemia: A Case Report. Intern Med. 2018.
  2. Yasuda H, Tsutsui M, Ota Y, Tanaka M, Komatsu N. Indolent T-lymphoblastic proliferation concomitant with acinic cell carcinoma mimicking T-lymphoblastic lymphoma: case report and literature review. Histopathology. 2018;72(5):862-6.
  3. Yamamoto T, Kamijo A, Nakazawa T, Nakajima K, Kirito K, Komatsu N, Masuyama K. A Very Rare Case of Hypereosinophilic Syndrome Secondary to Natural Killer/T-Cell Lymphoma. Case Rep Otolaryngol. 2018;2018:5965029.
  4. Watanabe N, Gotoh A, Shirane S, Hamano Y, Hirai Y, Shimizu M, Nakamura A, Matsumoto K, Morita K, Mori T, Ohsaka A, Komatsu N. Breakthrough Exophiala dermatitidis infection during prophylactic administration of micafungin during second umbilical cord blood transplantation after graft failure. Transpl Infect Dis. 2018;20(2):e12833.

海外学会発表

  1. Araki M, Masubuchi N, Hayashi E, Yang Y, Imai M, Kihara Y, Mizukami Y, Hironaka Y, Edahiro Y, Ohsaka A, Komatsu N. Boarding on the secretary pathway is required for the oncogenic property of mutant calreticulin. 23rd Congress of the European Hematology Association. Stockholm, Sweden. June, 2018.
  2. Edahiro Y, Mano S, Takei H, Li L, Morishita S, Gotoh A, Tsuneda S, Ohsaka A, Araki M, Komatsu N. Copy number of JAK2V617F modulates human hematopoietic cell differentiation. 8th International Conference on Myeloproliferative Neoplasms; 2018 15-May; SAGGART(DUBLIN), IRELAND.
  3. Nitta H, Gotoh A, Tanaka M, Ochiai T, Ota Y, Komatsu N. The Presence of Pleural Effusion at Diagnosis Predicts Poor Outcomes in Diffuse Large B-Cell Lymphoma Patients with MYC-Rearrangement or Double Protein Expression. 59th Annual Meeting of the American Society of Hematology and Exposition; 2017 11-Dec; Atlanta, USA.

国内学会発表

  1. 木下量介, 石橋真理子, 半田寛, 佐々木純, 今井陽一, 田中紀奈, 田野崎栄, 伊藤薫樹, 磯田淳, 朝山敏夫, 猪口孝一, 小松則夫, 田中淳司, 松本守生, 小池道明, 田村秀人. 多発性骨髄腫における病期分類と予後因子の検討:KT-MM予後因子解析. 第43回日本骨髄腫学会学術集会; 2018 年5月13日; 東京ベイ幕張ホール.
  2. 瀧澤春子, 関口康亘, 飯塚弘子, 若林睦, 杉元啓二, 坂尻さくら, 小松則夫, 野口雅章. 自家末梢血幹細胞移植に抵抗性で人工透析導入となるもボルテゾミブが奏功した原発性アミロイドーシスの一例. 第40回日本造血細胞移植学会; 2018年2月2日; 札幌市教育文化会館.
  3. 瀧澤春子, 関口康宣, 瀧澤春子, 飯塚弘子, 坂尻さくら, 杉元啓二, 冨田茂樹, 泉浩, 大久保光夫, 中村紀子, 澤田朝寛, 小松則夫, 野口雅章. 当科でCafizomibを投与した再発難治性多発性骨髄腫3例の使用経験. 第43回日本骨髄腫学会; 2018年5月12日; 東京ベイ幕張ホール千葉市.
  4. 舛井嘉大, 関口康宣, 杉元啓二, 坂尻さくら, 若林睦, 瀧澤春子, 飯塚弘子, 小松則夫, 野口雅章. 多彩な染色体異常のEBV-positiveHHV-8?unrelatedPEL-likelargeB-celllymphomaの1例. 第58回日本リンパ網内学会; 2018年6月30日; 名古屋市.
  5. 若林睦, 関口康宣, 飯塚弘子, 杉元啓二, 坂尻さくら, 冨田茂樹, 泉浩, 中村紀子, 澤田朝寛, 大久保光夫, 小松則夫, 野口雅章. 自家末梢血幹細胞移植後day11に突然死した原発性アミロイドーシスの一例. 第40回日本造血細胞移植学会; 2018年2月2日; 札幌市教育文化会館.
  6. 若林睦, 関口康宣, 瀧澤春子, 飯塚弘子, 坂尻さくら, 杉元啓二, 冨田茂樹, 泉浩, 大久保光夫, 中村紀子, 澤田朝寛, 小松則夫, 野口雅章. 当科でのPomalidomide(POM)10例の使用経験. 第43回日本骨髄腫学会; 2018年5月12日; 東京ベイ幕張ホール千葉市.